2763596-71-8
2763596-71-8
Chemical Structure
Olgotrelvir
Synonym(s): STI-1558
- CAS No.: 2763596-71-8
- Formula:C22H30N4O7S
- Molecular Weight:494.56
InChIKey: IICZZAVAIPTWCL-HBIMBUPRSA-N
SMILES: O=C(NCC1)[C@@H]1C[C@@H](C(O)S(=O)(O)=O)NC([C@H](CC(C)C)NC(C2=CC3=CC=CC=C3N2)=O)=O
Biological Activity: Olgotrelvir (STI-1558) is an orally active dual inhibitor of coronavirus main protease (Mpro) and human cell cathepsin (Cathepsin L). Olgotrelvir is readily converted to its active form, AC1115, in full blood and/or plasma. Olgotrelvir can effectively inhibit both SARS-CoV-2 replication and entry into host cells[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Olgotrelvir | Olgotrelvir (STI-1558) is an orally active dual inhibitor of coronavirus main protease (Mpro) and human cell cathepsin (Cathepsin L). Olgotrelvir is readily converted to its active form, AC1115, in full blood and/or plasma. Olgotrelvir can effectively inhibit both SARS-CoV-2 replication and entry into host cells. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19.
- [2]. Mao L, et al. Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19. Med. 2024 Feb 9;5(2):169-171. [Content Brief]
Keywords
